Human leukocyte antigen-based cancer immunotherapy
The highly polymorphic nature of human leukocyte antigen (HLA) class I alleles across global populations profoundly influences tumor antigen presentation and impacts on individual responses to immunotherapy.
Most FDA-approved HLA-based therapies for solid tumors are limited to patients with HLA-A*02 allele subtypes.
HLA allotype-driven cancer health disparities (HACHD) research examines how HLA allele genetics, biology, and population distribution influence immune responses, immunotherapy design, accessibility, and clinical outcomes.
Broad-spectrum HLA-based therapeutic strategies seek to expand T cell immunotherapy access to patients carrying nonHLA-A*02 allele subtypes.
The incorporation of artificial intelligence (AI)-driven platforms into the design of broad-spectrum and personalized HLA-based therapy could expand clinical trial eligibility and boost favorable treatment outcomes across genetically heterogeneous patient populations.
https://www.cell.com/trends/cancer/fulltext/S2405-8033(25)00224-9
